Arrivent Biopharma, Common Stock Probability of Future Stock Price Finishing Under 17.76
| AVBP Stock | 29.96 0.85 2.92% |
ArriVent |
ArriVent BioPharma, Target Price Odds to finish below 17.76
The tendency of ArriVent Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to 17.76 or more in 90 days |
| 29.96 | 90 days | 17.76 | near 1 |
Based on a normal probability distribution, the odds of ArriVent BioPharma, to drop to 17.76 or more in 90 days from now is near 1 (This ArriVent BioPharma, Common probability density function shows the probability of ArriVent Stock to fall within a particular range of prices over 90 days) . Probability of ArriVent BioPharma, price to stay between 17.76 and its current price of 29.96 at the end of the 90-day period is about 74.46 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.32 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, ArriVent BioPharma, will likely underperform. Additionally ArriVent BioPharma, Common has an alpha of 0.035, implying that it can generate a 0.035 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). ArriVent BioPharma, Price Density |
| Price |
Predictive Modules for ArriVent BioPharma,
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ArriVent BioPharma,. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.ArriVent BioPharma, Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. ArriVent BioPharma, is not an exception. The market had few large corrections towards the ArriVent BioPharma,'s value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold ArriVent BioPharma, Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ArriVent BioPharma, within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.03 | |
β | Beta against Dow Jones | 1.32 | |
σ | Overall volatility | 3.18 | |
Ir | Information ratio | 0.02 |
ArriVent BioPharma, Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ArriVent BioPharma, for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ArriVent BioPharma, can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| ArriVent BioPharma, had very high historical volatility over the last 90 days | |
| Net Loss for the year was (69.33 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ArriVent BioPharma, generates negative cash flow from operations | |
| ArriVent BioPharma, has a poor financial position based on the latest SEC disclosures | |
| Over 77.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from seekingalpha.com: ArriVent BioPharma GAAP EPS of -0.61 beats by 0.11 |
ArriVent BioPharma, Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of ArriVent Stock often depends not only on the future outlook of the current and potential ArriVent BioPharma,'s investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ArriVent BioPharma,'s indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 32 M | |
| Cash And Short Term Investments | 150.4 M |
ArriVent BioPharma, Technical Analysis
ArriVent BioPharma,'s future price can be derived by breaking down and analyzing its technical indicators over time. ArriVent Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of ArriVent BioPharma, Common. In general, you should focus on analyzing ArriVent Stock price patterns and their correlations with different microeconomic environments and drivers.
ArriVent BioPharma, Predictive Forecast Models
ArriVent BioPharma,'s time-series forecasting models is one of many ArriVent BioPharma,'s stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary ArriVent BioPharma,'s historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about ArriVent BioPharma,
Checking the ongoing alerts about ArriVent BioPharma, for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for ArriVent BioPharma, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| ArriVent BioPharma, had very high historical volatility over the last 90 days | |
| Net Loss for the year was (69.33 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ArriVent BioPharma, generates negative cash flow from operations | |
| ArriVent BioPharma, has a poor financial position based on the latest SEC disclosures | |
| Over 77.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from seekingalpha.com: ArriVent BioPharma GAAP EPS of -0.61 beats by 0.11 |
Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma,'s price analysis, check to measure ArriVent BioPharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma, is operating at the current time. Most of ArriVent BioPharma,'s value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma,'s price. Additionally, you may evaluate how the addition of ArriVent BioPharma, to your portfolios can decrease your overall portfolio volatility.